Kurin, Inc., the inventor and manufacturer of the Kurin^® blood culture collection sets, announced that the US Patent and Trademark Office has rejected the relevant claims of the ‘483 patent that Magnolia Medical asserted against Kurin. The Patent Office determined that multiple examples of prior art render claims 1 and 24 unpatentable.

“We are pleased, but not surprised, to see this action from the USPTO,” said Bob Rogers, CEO of Kurin, Inc. “We strongly believe that we do not infringe the ‘483 patent, but also believe the patent was preceded by other inventions that should render it invalid. This first office action suggests that the Patent Office confirms our belief.”

“This USPTO action follows the recent Court order on the ongoing litigation where the Court opined that Kurin was likely to prevail on its noninfringement motion on Claim 1 and possibly Claim 24 as well. We make no assumptions as to the conclusion of these parallel paths, but remain confident that we are on the correct side of this issue and look forward to a successful outcome through both the Court and the USPTO.”

Kurin’s revolutionary 510(k) cleared approaches to the contaminated blood culture problem are based on elegantly simple, intuitive designs that require no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc., the inventor and manufacturer of the Kurin^® blood culture collection sets, announced today the full-scale launch of Kurin Jet, which has joined the Kurin Lock family. The original member of the Kurin Lock family, now named the Kurin Flash, is the market-leading product in this space. The Kurin Jet provides a significant technological advancement over Kurin Flash.

“We had earlier announced a limited commercial release and have been thrilled with responses from customers using Jet,” said Bob Rogers, CEO of Kurin, Inc. “Feedback from those using Jet has been very positive with clinicians amazed at how fast Jet works, and they appreciate the greater control it allows. Automated manufacturing has started, and we are now able to provide this next generation product more widely. Kurin Jet can be used with direct to media, syringe draw, direct venipuncture and PIV applications.”

“Kurin Flash became the market-leading product because of its small size, small amount of blood required and ease of use. Compliance is the key to improving clinical outcomes and the increased speed and control make Kurin Jet even easier to use, helping hospitals address this important clinical problem.

Kurin’s revolutionary approach to the contaminated blood culture problem is based on elegantly simple, intuitive designs that require no additional user steps. Like the Kurin Flash, Kurin Jet passively sidelines potential contaminants during blood culture collection. Kurin Flash and Kurin Jet both provide a better and more sustainable approach than active, conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Flash and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc., the inventor and manufacturer of the Kurin^® blood culture collection sets, announced today that the Food and Drug Administration has issued a 510(k) clearance for the Kurin product line. Kurin now has four 510(k) clearances from the FDA. The recent clearance says, in part, that Kurin reduces the frequency of blood culture contaminations*.

“We are pleased that the FDA has provided clearance to say that Kurin reduces blood culture contaminations” said Bob Rogers, CEO of Kurin, Inc. “Kurin is the market leader because our device is simple to use and requires a minimal amount of blood. Our submission to the FDA included data demonstrating dramatic decreases in contaminations while using Kurin. The new 510(k) highlights Kurin’s growing list of accomplishments and underscores why Kurin continues to be the #1 company addressing blood culture contaminations. This is yet further proof that the myth that blood must be isolated to achieve contamination reduction is simply wrong.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

*Kurin Lock allows the specimen of blood from the patient to be sidelined prior to the collection of the test sample to reduce the frequency of blood culture contamination when contaminates are present in the initial blood sample compared to blood cultures drawn using standard practice without the Kurin Lock.

The Emergency Nurses Association on Tuesday announced its 2023 Corporate Engagement Council, which includes Kurin, Inc., as its newest member.

Created in 2019, the CEC brings ENA and industry leaders together with a focus on innovation and advances in emergency nursing education, advocacy and research. Council members also participate in dedicated sessions with ENA Board members and leaders centered on discussion of, and planning for, future initiatives to advance emergency nursing.

The 2023 Corporate Engagement Council includes: Bioexcel Therapeutics, BrainScope, Chamberlain University, Elsevier, HealthStream, Magnolia, Mednition, Stryker, Teleflex and now Kurin.

“ENA prides itself on having a strong relationship with industry partners who deeply value emergency nurses and the ways they provide care to patients,” said ENA President Terry Foster, MSN, RN, CEN, CPEN, CCRN, TCRN, FAEN. “Kurin’s emphasis on innovative, clinician-approved technologies makes it a great addition to the CEC.”

Kurin CEO Bob Rogers described a natural connection between Kurin and ENA, which he called a vital organization that provides leadership and a wide variety of resources to emergency department nurses.

“We are pleased to have received the invitation from the ENA to join its council,” Rogers said. “Kurin has become the market leader by providing an easy-to-use solution to reduce blood culture contamination and our goal is to work with the ENA to help their members improve clinical outcomes.”

For more information on ENA’s Corporate Engagement Council, visit ena.org/corporate-support/cec.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc., the inventor and manufacturer of the Kurin^® blood culture collection sets, provides an update to the most recent moves by Magnolia Medical Technologies. This week, Magnolia filed a motion in the US District Court of Delaware for a permanent injunction, hoping to take Kurin off the market.

“We are disappointed, but not surprised by their attempt to create a monopoly and deprive customers of the ability to choose the most appropriate solution for them,” said Bob Rogers, CEO and Inventor of Kurin. “We will vigorously defend access to the best solution to the contaminated blood culture problem. Our experience over the past few years shows that hospitals have rejected Magnolia’s Steripath product because it is unnecessarily complex and difficult to use.  Kurin’s innovation in developing a smaller, simpler device is a demonstration of how the intellectual property system should work in America and explains why we are the market leader. We will not be bullied by a venture-backed company who continues to spend their millions on litigation in hopes of creating a monopoly. We are heartened by the support of Kurin customers, and have been told they too are upset at Magnolia’s attempts to use the legal system to reduce choice and negatively impact clinical outcomes.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening infections caused by C. diff.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.